FIELD: medicine, therapy.
SUBSTANCE: invention relates to treatment of vasculitis and erythematosus lupus. Method involves administration of 15-deoxyspergualine or its analogous by two or more courses with break for 4 days to 5 weeks. Period between successive injections of preparation within the treatment course is up to 48 h and the treatment course is at least 5-7 days. Method provides high treatment effect and reducing the total dose of 15-deoxyspergualine or its analogous.
EFFECT: enhanced effectiveness of treatment.
25 cl, 2 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING ONCOLOGICAL DISEASES | 2020 |
|
RU2741701C1 |
| TREATMENT OF AUTOIMMUNE DISEASES | 2006 |
|
RU2424795C2 |
| TREATING AUTOIMMUNE DISEASES | 2006 |
|
RU2493840C2 |
| APPLICATION OF CD25-BINDING MOLECULES FOR TREATMENT OF STEROID-RESISTANT PATIENTS | 2002 |
|
RU2318537C2 |
| METHOD FOR TREATING THE HEMORRHAGIC VASCULITIS IN CHILDREN | 2000 |
|
RU2187311C2 |
| PHARMACEUTICAL COMPOSITION, CONTAINING DERIVATIVES OF GLUTARIMIDES, AND THEIR APPLICATION FOR TREATMENT OF EOSINOPHILIC DISEASES | 2013 |
|
RU2552929C1 |
| METHOD OF EVALUATING IMMUNOSUPPRESSIVE RESPONSE RATE IN CHILDREN WITH CHRONIC GLOMERULONEPHRITIS | 2010 |
|
RU2425381C1 |
| METHOD FOR PRODUCING REGULATORY DENDRITIC CELLS | 2011 |
|
RU2597976C2 |
| APPLICATION OF SINGLE DOSE OF CD20-SPECIFIC BINDING MOLECULES | 2006 |
|
RU2421242C2 |
| MODIFIED IMMUNOMODULATING PARTICLES | 2011 |
|
RU2587853C2 |
